[go: up one dir, main page]

MX2021005171A - Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos. - Google Patents

Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos.

Info

Publication number
MX2021005171A
MX2021005171A MX2021005171A MX2021005171A MX2021005171A MX 2021005171 A MX2021005171 A MX 2021005171A MX 2021005171 A MX2021005171 A MX 2021005171A MX 2021005171 A MX2021005171 A MX 2021005171A MX 2021005171 A MX2021005171 A MX 2021005171A
Authority
MX
Mexico
Prior art keywords
erk inhibitors
inhibitors
erk
erk2
erk1
Prior art date
Application number
MX2021005171A
Other languages
English (en)
Inventor
Michael D Bartberger
Dylan Conklin
Dennis Slamon
Justin A Hilf
Brian M Stoltz
Michael J Palazzolo
Corey M Reeves
Brendan M O''boyle
Martina S Mcdermott
Neil A O''brien
Steven J Wittenberger
Oliver C Loson
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Publication of MX2021005171A publication Critical patent/MX2021005171A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción proporciona compuestos y composiciones que son inhibidores de ERK1, ERK2 o ambos, y métodos de uso de los mismos.
MX2021005171A 2018-11-16 2019-11-15 Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos. MX2021005171A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768565P 2018-11-16 2018-11-16
US201962908965P 2019-10-01 2019-10-01
PCT/US2019/061750 WO2020102686A1 (en) 2018-11-16 2019-11-15 Erk inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2021005171A true MX2021005171A (es) 2021-10-01

Family

ID=70730924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005171A MX2021005171A (es) 2018-11-16 2019-11-15 Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos.

Country Status (12)

Country Link
US (1) US20220002294A1 (es)
EP (1) EP3880677A4 (es)
JP (1) JP2022507514A (es)
KR (1) KR20210130701A (es)
CN (1) CN113423707A (es)
AU (1) AU2019381808A1 (es)
BR (1) BR112021009430A2 (es)
CA (1) CA3119988A1 (es)
IL (1) IL283106A (es)
MX (1) MX2021005171A (es)
SG (1) SG11202104404XA (es)
WO (1) WO2020102686A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756108A2 (en) * 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
CN101228160A (zh) * 2004-06-30 2008-07-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吖吲哚
UA95244C2 (ru) * 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
EP2318407B1 (en) * 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
DE102009043260A1 (de) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2012094313A1 (en) * 2011-01-04 2012-07-12 Kinentia Biosciences Llc Pyrazole derivatives as erk inhibitors
EP2763535B1 (en) * 2011-10-03 2017-06-07 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
WO2014060395A1 (en) * 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Serine/threonine kinase inhibitors
CN104903320B (zh) * 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
RS57058B1 (sr) * 2013-10-03 2018-05-31 Kura Oncology Inc Ekr inhibitori i postupci primene
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
JP2018502853A (ja) * 2015-01-23 2018-02-01 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド 炎症およびがんを処置するための複素環式ｉｔｋ阻害剤
EP3170822A1 (en) * 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
CN107973783B (zh) * 2016-10-21 2024-09-06 正大天晴药业集团股份有限公司 作为erk抑制剂的苯胺嘧啶衍生物
CN108948002A (zh) * 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Also Published As

Publication number Publication date
CA3119988A1 (en) 2020-05-22
EP3880677A4 (en) 2022-06-22
SG11202104404XA (en) 2021-05-28
WO2020102686A1 (en) 2020-05-22
IL283106A (en) 2021-06-30
AU2019381808A1 (en) 2021-05-27
EP3880677A1 (en) 2021-09-22
US20220002294A1 (en) 2022-01-06
BR112021009430A2 (pt) 2021-08-17
JP2022507514A (ja) 2022-01-18
KR20210130701A (ko) 2021-11-01
CN113423707A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A3 (en) Tead inhibitors and uses thereof
ZA201906822B (en) Indole ahr inhibitors and uses thereof
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
PH12021500026A1 (en) Irak degraders and uses thereof
PH12022551524A1 (en) Irak degraders and uses thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
IL276082A (en) DNA-pk inhibitor compounds, preparations containing them and their uses
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2018006288A (es) Inhibidores de acc tipo ester y usos de los mismos.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
IL276080A (en) DNA-pk suppressor compounds, UTP-containing preparations and their uses
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
ZA202309446B (en) Rapamycin analogs and uses thereof